1100 Winter Street
Waltham, MA 02451
United States
617 433 2605
https://www.allovir.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 15
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. David L. Hallal | Executive Chairman of the Board | 200k | N/A | 1966 |
Dr. Diana M. Brainard M.D. | CEO & Director | 636.63k | N/A | 1972 |
Mr. Vikas Sinha C.A., CPA, M.B.A. | President, CFO & Director | 373.04k | N/A | 1963 |
Mr. Edward Miller J.D. | General Counsel & Secretary | 461.66k | N/A | 1965 |
Mr. Brett R. Hagen | Chief Accounting Officer | N/A | N/A | 1973 |
Dr. Ann M. Leen Ph.D. | Chief Scientific Officer | N/A | N/A | 1977 |
Ms. Cintia Piccina Pharm.D. | Chief Commercial Officer | N/A | N/A | 1974 |
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
AlloVir, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 10. The pillar scores are Audit: 8; Board: 10; Shareholder Rights: 8; Compensation: 10.